<DOC>
	<DOCNO>NCT01310465</DOCNO>
	<brief_summary>Many patient lumbar degenerative disease suffer osteoporosis reduce bone mass low bone mineral density . Among patient lumbar degenerative disease , need fusion surgery . But condition osteoporosis low bone mineral density slow rate bone fusion , reduce success bone fusion , ultimately affect overall effectiveness surgery . Zoledronic acid effective anti-osteoporotic . Many researcher dispute zoledronic acid promote heal long bone fracture . But researcher focus effect zoledronic acid lumbar fusion . In study , select patient lumbar degenerative disease lumbar interbody fusion surgery . Three day postoperatively , patient randomize either one infusion zoledronic acid sodium chloride intravenously . We follow patient 6 month . During time , detect bone metabolism bone fusion patient . At last , tell zoledronic acid modify bone metabolism promote bone fusion .</brief_summary>
	<brief_title>The Effect Zoledronic Acid Bone Fusion Bone Metabolism Patients With Lumbar Degenerative Disease After Lumbar Interbody Fusion</brief_title>
	<detailed_description />
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Patients lumbar degenerative disease lumbar interbody fusion surgery Age 5070 year old Willing sign inform consent Application strontium ranelate , sodium fluoride parathyroid hormone Application bisphosphonates 8 week 2 year preoperatively Suffering bone fracture 3 month preoperatively Urinary creatinine clearance rate le 35mL/min Serum calcium concentration great 2.75mmol/L less 2.00mmol/L Pregnancy breastfeed woman Suffering cancer disease may expect live less year</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>